The assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics

Drug hepatotoxicity assessment is a relevant issue both in the course of drug development as well as in the post marketing phase. The use of human relevant in vitro models in combination with powerful analytical methods (metabolomic analysis) is a promising approach to anticipate, as well as to unde...

Full description

Saved in:
Bibliographic Details
Main Authors: Guillermo Quintás (Author), José V. Castell (Author), Marta Moreno-Torres (Author)
Format: Book
Published: Frontiers Media S.A., 2023-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9edcedea08d04a0ba85d5c79e9afb9c5
042 |a dc 
100 1 0 |a Guillermo Quintás  |e author 
700 1 0 |a Guillermo Quintás  |e author 
700 1 0 |a José V. Castell  |e author 
700 1 0 |a José V. Castell  |e author 
700 1 0 |a José V. Castell  |e author 
700 1 0 |a Marta Moreno-Torres  |e author 
700 1 0 |a Marta Moreno-Torres  |e author 
700 1 0 |a Marta Moreno-Torres  |e author 
245 0 0 |a The assessment of the potential hepatotoxicity of new drugs by in vitro metabolomics 
260 |b Frontiers Media S.A.,   |c 2023-05-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2023.1155271 
520 |a Drug hepatotoxicity assessment is a relevant issue both in the course of drug development as well as in the post marketing phase. The use of human relevant in vitro models in combination with powerful analytical methods (metabolomic analysis) is a promising approach to anticipate, as well as to understand and investigate the effects and mechanisms of drug hepatotoxicity in man. The metabolic profile analysis of biological liver models treated with hepatotoxins, as compared to that of those treated with non-hepatotoxic compounds, provides useful information for identifying disturbed cellular metabolic reactions, pathways, and networks. This can later be used to anticipate, as well to assess, the potential hepatotoxicity of new compounds. However, the applicability of the metabolomic analysis to assess the hepatotoxicity of drugs is complex and requires careful and systematic work, precise controls, wise data preprocessing and appropriate biological interpretation to make meaningful interpretations and/or predictions of drug hepatotoxicity. This review provides an updated look at recent in vitro studies which used principally mass spectrometry-based metabolomics to evaluate the hepatotoxicity of drugs. It also analyzes the principal drawbacks that still limit its general applicability in safety assessment screenings. We discuss the analytical workflow, essential factors that need to be considered and suggestions to overcome these drawbacks, as well as recent advancements made in this rapidly growing field of research. 
546 |a EN 
690 |a metabolomics 
690 |a drug hepatotoxicity 
690 |a mechanisms of hepatotoxicity 
690 |a in vitro 
690 |a HepG2 cells 
690 |a primary hepatocytes 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 14 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1155271/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/9edcedea08d04a0ba85d5c79e9afb9c5  |z Connect to this object online.